Found Company Overview & Business Model: Is It Legit?

What Is Found and How Does Its Business Model Work?

Found operates as a direct-to-consumer telehealth company focused on obesity medicine. Patients complete an online intake, receive a clinical evaluation from an affiliated licensed clinician, and, if appropriate, get a prescription sent to a pharmacy. The platform charges a monthly membership fee separate from medication costs, which distinguishes it from pharmacy-only programs.

The Membership-Plus-Medication Structure

The membership fee, roughly $99 per month as of early 2025, covers clinician access, care team messaging, and the Found app. Medications are billed through pharmacy benefit managers or paid out-of-pocket. This two-part cost structure is common across GLP-1 telehealth companies and can make total monthly spending opaque to new members.

BCBS Partnerships and Insurance Coverage

Found has established agreements with select Blue Cross Blue Shield plans, allowing members whose employers participate to receive partial or full reimbursement. Coverage terms vary sharply by employer and plan tier. The FDA-approved anti-obesity medication (AOM) field changed in 2023 when the Biden administration proposed Medicare Part D coverage for AOMs, which could eventually expand reimbursement broadly, though that rule remains unsettled as of this writing.

How Found Makes Money

Revenue comes from three channels: monthly memberships, pharmacy partnership referral arrangements, and, increasingly, employer wellness contracts. Employer contracts, which bypass individual consumer acquisition costs, represent the highest-margin segment for most telehealth weight-management companies. Found has explicitly targeted mid-size employer groups as a growth segment.

What Does Found Prescribe?

Found prescribes a wider range of weight-management drugs than competitors that focus exclusively on GLP-1 agonists. The formulary includes FDA-approved GLP-1 receptor agonists and several non-GLP-1 options.

GLP-1 Agonists

The backbone of Found's clinical offering is semaglutide and tirzepatide, the two most studied anti-obesity medications available today. In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo [1]. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% with placebo [2]. These are the benchmark figures any GLP-1 prescriber should quote to patients before starting therapy.

Found prescribes the brand-name injectable formulations (Wegovy, Zepbound) through standard specialty pharmacies and, where it is available, oral semaglutide (Rybelsus), though the oral form is FDA-approved only for type 2 diabetes, not obesity, a prescribing nuance patients should clarify.

Non-GLP-1 Medications

Found's broader formulary includes:

• Bupropion-naltrexone (Contrave): FDA-approved for chronic weight management; average weight loss of approximately 5% over 56 weeks in the COR-I trial (N=1,742) [3].
• Topiramate (off-label): Combined with phentermine in the FDA-approved Qsymia formulation; topiramate alone is used off-label at lower doses.
• Metformin (off-label for weight): Used to blunt weight gain from medications and improve insulin sensitivity.
• Orlistat (Xenical, Alli): Reduces dietary fat absorption; modest 2.9% incremental weight loss versus placebo in meta-analysis [4].
• Phentermine (short-term Schedule IV controlled substance): FDA-approved for short-term use, less than 12 weeks.

Compounded Semaglutide (Status as of 2025)

During the 2022 to 2024 FDA shortage period, many telehealth platforms, including Found, provided access to compounded semaglutide through 503A and 503B pharmacies. The FDA removed semaglutide from the shortage list in February 2025, which makes continued dispensing of compounded semaglutide from most pharmacies legally problematic. Patients currently receiving compounded formulations should ask Found's clinical team directly which compounding pharmacies it works with and whether those pharmacies hold active 503B outsourcing facility status [5].

Is Found Legit? Assessing Clinical Credibility

The question "is Found legit" usually asks two things at once: Is it a real medical service, and does the treatment actually work?

Regulatory and Licensing Status

Found operates under standard U.S. Telehealth prescribing rules. Its affiliated clinicians hold state licensure, and prescriptions are routed through licensed pharmacies. The platform follows state-specific telehealth prescribing regulations, which vary on controlled-substance prescribing. Found is not accredited by the American Board of Obesity Medicine (ABOM), though individual clinicians on its network may hold ABOM certification.

Does Found-Prescribed Treatment Work?

No randomized trial has been published specifically on outcomes among Found members. The efficacy question therefore defaults to the underlying drugs. The American Gastroenterological Association's 2022 Clinical Practice Guideline states: "We recommend pharmacological therapy for adults with obesity (BMI 30 kg/m² or greater) or overweight (BMI 27 to 29.9 kg/m² with at least one weight-related comorbidity) in combination with lifestyle interventions" [6]. Found's clinical model aligns structurally with that recommendation, though whether its behavioral coaching component meets guideline quality thresholds is unknown.

Patient Retention and Dropout Risk

GLP-1 therapy has a high dropout rate in real-world settings. A 2023 analysis of U.S. Pharmacy claims data found that only 44.7% of patients who initiated semaglutide or liraglutide for weight management were still filling prescriptions at 12 months [7]. Telehealth platforms that lack strong side-effect management support may see even lower retention. Found provides asynchronous messaging with care teams, which may not substitute adequately for synchronous clinical support during dose escalation.

HealthRX Clinical Triage Framework: When to Use Found vs. An In-Person Obesity Medicine Specialist

| Patient Profile | Found (Telehealth) Appropriate? | Reasoning | |---|---|---| | BMI 27 to 39, no complex comorbidities | Likely yes | Straightforward AOM initiation; async model sufficient | | BMI 40 or greater or BMI 30+ with cardiovascular disease, sleep apnea, or kidney disease | Prefer in-person specialist | Requires cardiology or nephrology coordination | | Prior bariatric surgery | No | Drug-nutrient interactions require specialist oversight | | Active eating disorder history | No | Standard telehealth intake screens are inadequate | | Needs phentermine or controlled substances | State-dependent | Check Found's controlled-substance prescribing state list | | Employer BCBS coverage available | Yes, confirm first | Can significantly reduce out-of-pocket burden |

How Much Does Found Cost?

Pricing has three components that patients often conflate.

Membership Fee

The platform access fee is approximately $99 per month. Annual prepayment may reduce this to roughly $79 per month.

Medication Cost

This is the largest variable. Brand-name Wegovy (semaglutide 2.4 mg) lists at approximately $1,349 per month without insurance. Zepbound (tirzepatide) lists at approximately $1,059 per month. With Novo Nordisk's or Eli Lilly's savings cards, commercially insured patients may pay as low as $25 per month, but those cards exclude government-insured patients (Medicare, Medicaid). Non-GLP-1 generics are far cheaper; bupropion-naltrexone generics run $30 to $80 per month at most retail pharmacies.

Lab and Ancillary Costs

Found does not bundle lab work into the membership fee. Initial metabolic panels and follow-up HbA1c or lipid panels, which good obesity medicine practice requires before and during GLP-1 therapy, are billed separately through the patient's insurance or paid out of pocket at roughly $40 to $150 per draw.

Found vs. Alternatives: How Does It Compare?

Several telehealth platforms compete in the same space. Each differs meaningfully on formulary access, cost, and clinical depth.

Found vs. Ro Body

Ro Body focuses almost exclusively on branded and compounded GLP-1s with a simpler one-fee model. Found's advantage is its broader non-GLP-1 formulary, which matters for patients who cannot tolerate GLP-1 side effects or for whom GLP-1s are contraindicated (personal or family history of medullary thyroid carcinoma or MEN2 syndrome).

Found vs. Calibrate

Calibrate historically required a one-year commitment and offered a stronger structured behavior-change curriculum. Found is month-to-month and app-based, with lighter behavioral support. Calibrate exited the consumer market in 2024 and pivoted to employer contracts, so direct comparison is now largely moot for individual consumers.

Found vs. WeightWatchers (WeightWatchers Clinic)

WeightWatchers relaunched as a GLP-1 telehealth service after acquiring Sequence in 2023. Its platform carries strong brand recognition and a proven behavioral-support track record from its legacy program. Found offers a broader medication menu. WeightWatchers may suit patients who want a structured behavioral program tightly integrated with prescribing.

Found vs. Noom Med

Noom Med combines Noom's psychology-based app with GLP-1 prescribing. It excels in behavioral change tools, which aligns with the AHA's position that "behavioral interventions combined with pharmacotherapy produce greater and more sustained weight loss than either approach alone" [8]. Found offers more medication choices; Noom Med offers deeper behavioral scaffolding.

GLP-1 Weight Loss: What the Evidence Actually Says

Regardless of which platform prescribes a GLP-1, the drug's efficacy data belongs to the drug, not the platform. Patients should understand both what the best-case outcomes look like and what the real-world data shows.

Clinical Trial Benchmarks

• STEP-1 (N=1,961): Semaglutide 2.4 mg, 14.9% mean weight loss at 68 weeks, P<0.001 versus placebo [1].
• SURMOUNT-1 (N=2,539): Tirzepatide 15 mg, 20.9% mean weight loss at 72 weeks, P<0.001 [2].
• SCALE Obesity and Prediabetes (N=3,731): Liraglutide 3.0 mg, 8.0% mean weight loss at 56 weeks [9].

Cardiovascular Evidence

The SELECT trial (N=17,604) showed semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in adults with obesity and pre-existing cardiovascular disease but without diabetes, hazard ratio 0.80 (95% CI 0.72 to 0.90) [10]. This is the strongest cardiovascular outcome datum available for any GLP-1 anti-obesity therapy and should factor into prescribing decisions for high-risk patients.

What Happens When You Stop

Weight regain after GLP-1 discontinuation is substantial. The STEP-4 withdrawal trial showed that participants who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight by 52 weeks post-discontinuation [11]. Found's marketing should, but does not always, prominently disclose this. Patients who start GLP-1 therapy through any telehealth platform should plan for indefinite or very long-term treatment if their underlying biology requires it.

Common Side Effects and How Found Manages Them

Nausea, vomiting, constipation, and diarrhea affect 30 to 40% of GLP-1 users, primarily during dose escalation. Found's care team communication is asynchronous, meaning patients experiencing significant GI side effects may wait hours for a clinician response. For mild nausea manageable with dietary adjustments, this is acceptable. For dehydration or severe vomiting, patients need real-time care that a chat-based telehealth model cannot reliably provide.

Found Reviews: What Are Real Patients Saying?

Patient reviews on independent platforms (Trustpilot, Reddit's r/Semaglutide, Better Business Bureau) show a pattern consistent with most telehealth weight-loss services.

Positive Themes

Positive reviews cluster around three areas: prescription access for patients who could not get GLP-1s from their primary care physician, the non-GLP-1 fallback options when GLP-1s are unaffordable, and ease of the intake process.

Negative Themes

Negative reviews cite delays in prescription processing during shortage periods, difficulty reaching clinical staff during side-effect management, and unexpected billing charges when insurance coverage changed mid-membership. Several BBB complaints involve difficulty canceling after a billing cycle begins.

What Review Patterns Cannot Tell You

Patient reviews measure satisfaction, not outcomes. A patient satisfied with quick prescription access may still have poor clinical outcomes. Conversely, a patient frustrated by slow response times may be achieving excellent metabolic results. No patient-review platform stratifies reviews by actual weight-loss achieved or by safety events, making them a weak signal for clinical decision-making.

Who Should Consider Found?

Found fits a specific clinical profile reasonably well.

Good Candidates

Adults with BMI 30 or greater, or BMI 27 or greater with at least one weight-related comorbidity, who have no contraindications to the available medications and whose primary care physician has been unwilling to prescribe GLP-1s or AOMs. Patients covered by a participating BCBS employer plan who want to reduce out-of-pocket costs. Patients who need a non-GLP-1 AOM such as bupropion-naltrexone because GLP-1s are contraindicated or unaffordable.

Poor Candidates

Patients with complex cardiovascular disease, significant kidney or liver impairment, a history of pancreatitis, personal or family history of medullary thyroid carcinoma, active eating disorders, or any clinical situation requiring close synchronous monitoring. These patients need in-person obesity medicine specialists, ideally ABOM-certified, who can coordinate with relevant subspecialists.

The Obesity Medicine Association recommends that patients with BMI above 40 or with severe comorbidities be managed by physicians with obesity medicine training rather than general telehealth intake models [12].